18 months ago, weight-loss peptides looked like they might fundamentally reshape healthcare demand patterns overnight. Investors treated semaglutide and tirzepatide as existential threats to multiple device categories, from cardiovascular technologies to orthopedics, diabetes management, and surgical interventions. Today, the latest data suggests the obesity treatment market is evolvi... https://www.lifesciencemarketresearch.com/insights/peptides-medtech-and-the-obesity-treatment-market